Molybdenum cofactor deficiency type A (MOCS1) OMIM 252150

In Molybdenum cofactor deficiency type A (MOCS1, OMIM 252150), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4752, γ 1.3787, spinodal 0.6231). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Molybdenum cofactor deficiency type A is an R19 double-well emerged from the real proximal-promoter DNA of MOCS1. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.3787
barrier
0.4752
spinodal
0.6231
s_on / s_off
1.1742 / -1.1742
fragility
0.57
corrective polarity
supply
forced direction
raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.4752 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: increasegeometric rank 0.57
Mechanism. supply / restore the positive drive (replace-or-agonise the missing competence)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If supplying/agonising cyclic pyranopterin monophosphate (cPMP) competence (raising the switch drive) does NOT move the DOWN [F] switch toward the healthy branch in a MOCS1-deficient model, the h-restore(supply) lever is refuted for this axis.
gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00
Mechanism. N/A
Applies to. none (honest exclusion)
EXCLUDED: null allele -- no product to stiffen
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual MOCS1 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: fosdenopterin (synthetic cyclic pyranopterin monophosphate, cPMP, substrate replacement). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)dir.statusphasemap
fosdenopterin (synthetic cyclic pyranopterin monophosphate, cPMP, substrate replacement)
Reiss 1998 Hum Genet 103:639; Veldman 2010 Pediatrics 125:e1249
increaseapproved4✓ in use
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Direction-only candidate leads (corpus join)

Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.

fosdenopterin (cyclic pyranopterin monophosphate, cPMP)✓ recovered standarddir: increase · approved
Class. synthetic cyclic pyranopterin monophosphate (cPMP) substrate replacement
Mechanism. Supplies the cyclic pyranopterin monophosphate the MOCS1 step can no longer make, restoring downstream molybdenum-cofactor competence. Direction: increase the deficient species. Scope: agnostic (downstream substrate replacement).
✓ This is a rediscovery. Fosdenopterin is approved for molybdenum cofactor deficiency type A; the direction logic recovered an established treatment.
Safety (qualitative; no magnitude). approved-use safety profile on record (qualitative; no magnitude)
Falsifier. If fosdenopterin (cyclic pyranopterin monophosphate, cPMP) (a gene-specific supply/increase agent) does NOT move the DOWN [F] switch toward the healthy branch in a MOCS1-deficient model, the h-restore(supply) direction is refuted for fosdenopterin (cyclic pyranopterin monophosphate, cPMP) here.
Source: FDA label: fosdenopterin for molybdenum cofactor deficiency type A
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
elementgradebasis
R19 switch & cusp geometry (this page)[V] verifiedemerged from measured promoter γ of MOCS1; deterministic, 2×sha256 identical
corrective direction[F] forcedforced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads[O] opendirection-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).